Jing Yang

Associate Professor

Email: jingyang@cmpt.ac.cn

Dr. Yang joined the Innovative Drug Research faculty of IHMT in 2021. Her current research is focused on promoting degradation of immune-regulators and cancer driver proteins through small molecule modulation of the cellular machinery that regulates proteostasis.

 

 

 

EDUCATION BACKGROUND

2010.9-2015.7, PhD/Microbiology, Institut Pasteur of Shanghai, Chinese Academy of Sciences.

2005.9-2009.7, B.S./Biotechnology, Shandong University. School of life Science, China.

 

RESEARCH EXPERIENCE

2021.1-Present , Assistant Professor, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences,

2015.11-2020.11, Post-doctoral Research Fellow, Cancer Biology, Dana-Farber Cancer Institute, Harvard medical School.

PUBLICATIONS

  1. Jing Yang#, Ellen L. Weisberg#, Shuang Qi#, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S. Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J. Buhrlage*, Qingsong Liu*, James D. Griffin*. Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia Jan 2022. doi: 10.1038/s41375-021-01494-w.
  2. Jing Yang#, Ellen L. Weisberg#, Xiaoxi Liu#, Robert Magin, Wai Cheung Chan, Bin Hu, Nathan Schauer, Shengzhe Zhang, Ilaria Lamberto, Laura Doherty, Chengcheng Meng, Martin Sattler, Lucia Cabal-Hierro, Eric Winer, Richard Stone, Jarrod Marto, James Griffin*, Sara Buhrlage*. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia 2022.36: 210–220. doi: 10.1038/s41375-021-01336-9.
  3. Jing Yang*, Ellen L. Weisberg. HSP70 and FLT3-ITD: targeting chaperone system to overcome drug resistance. Blood Science 2021，3 (04): 151-153.
  4. Jing Yang#, Ping Wei#, Joseph Barbi, Qianru Huang, Evan Yang, Yakun Bai, Jia Nie, Yanhang Gao, Jinhui Tao, Ying Lu, Chichu Xie, Xiaoxia Hou, Jiazi Ren, Xingmei Wu, Jian Meng, Ying Zhang, Juan Fu, Wei Kou, Yayi Gao, Zuojia Chen, Rui Liang, Andy Tsun, Dan Li, Wenzhi Guo, Shuijun Zhang, Song-Guo Zheng, Junqi Niu, Paul Galardy, Xuemei Tong, Guochao Shi, Huabin Li*, Fan Pan* and Bin Li*. The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation. EMBO Reports 2020, 21 (9): e50308. doi: 10.15252/embr.202050308.
  5. Jing Yang#, Chengcheng Meng#, Ellen L. Weisberg#, Ilaria Lamberto, Martin Sattler, Nathanael S. Gray, Sara J. Buhrlage*, James D. Griffin*. Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer 2020, 122 (8): 1175-1184. doi: 10.1038/s41416-020-0731-z.
  6. Ellen L. Weisberg#, Nathan J. Schauer#, Jing Yang#, Ilaria Lamberto#, Laura Doherty, Shruti Bhatt, Atsushi Nonami, Chengcheng Meng, Anthony Letai, Renee Wright, Hong Tiv, Prafulla C. Gokhale, Maria Stella Ritorto, Virginia De Cesar, Matthias Trost, Alexandra Christodoulou, Amanda Christie, David M. Weinstock, Sophia Adamia, Richard Stone, Dharminder Chauhan, Kenneth C. Anderson, Hyuk-Soo Seo, Sirano Dhe-Paganon, Martin Sattler, Nathanael S. Gray, James D. Griffin*, Sara J. Buhrlage*. Inhibition of USP10 induces degradation of oncogenic FLT3，Nature Chemical Biology 2017, 13 (12): 1207-1215. doi: 10.1038/nchembio.2486.